Positive top-line results shown for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) in adults with binge eating disorder
Shire plc (LSE: SHP, NASDAQ: SHPG) announces positive top-line results from two identically designed randomized placebo-controlled Phase 3 studies evaluating the efficacy and safety of Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) versus placebo in adults with binge eating disorder (BED). In both studies Vyvanse was found to be statistically superior to placebo on the primary efficacy analysis (p-value "We are extremely pleased with these results, and will be working expeditiously to submit an application to the U.S... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 6, 2013 Category: Consumer Health News Tags: Eating Disorders Source Type: news
Shire's ADHD drug succeeds in trial to treat binge eating
LONDON (Reuters) - Pharmaceutical group Shire PLC said Vyvanse, its amphetamine-based drug prescribed to U.S. students to control ADHD, had also been successful in treating the newly-recognized binge eating disorder (BED) in a trial. (Source: Reuters: Health)
Source: Reuters: Health - November 5, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Lisdexamfetamine Dimesylate Demonstrates Significantly Faster Response, Greater Reductions Of Core ADHD Symptoms Than Atomoxetine In Study
Shire plc (LSE: SHP, NASDAQ: SHPG) presents scientific data comparing the efficacy and safety of the Attention Deficit/Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) at the 4th World Congress on ADHD, Milan, Italy. The study (SPD489-317) is the first head-to-head trial in children and adolescents with at least moderately symptomatic ADHD and an inadequate response to previous methylphenidate therapy... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 11, 2013 Category: Consumer Health News Tags: ADHD Source Type: news
Parents Think 1 In 100 Teens Using "Study Drugs" But Actual Figure Is More Like 1 In 10
As high schoolers prepare for final exams, teens nationwide may be tempted to use a "study drug" Â- a prescription stimulant or amphetamine - to gain an academic edge. But a new University of Michigan poll shows only one in 100 parents of teens 13-17 years old believes that their teen has used a study drug. Study drugs refer to stimulant medications typically prescribed for the treatment of attention deficit hyperactivity disorder (ADHD); commonly prescribed medicines in this category include Adderall, Concerta, Ritalin, and Vyvanse... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 22, 2013 Category: Consumer Health News Tags: Alcohol / Addiction / Illegal Drugs Source Type: news
ADHD Drug May Decrease Binge Eating EpisodesADHD Drug May Decrease Binge Eating Episodes
A new phase 2 trial suggests that lisdexamfetamine dimesylate can significantly reduce episodes of bingeing and improve behavior in patients with binge eating disorder. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 21, 2013 Category: Consumer Health News Tags: Psychiatry News Source Type: news
ADHD Drug Shows Promise for Binge Eating (CME/CE)
SAN FRANCISCO (MedPage Today) -- A stimulant drug, lisdexamfetamine dimesylate (Vyvanse), nearly abolished eating binges in adult patients who had experienced such episodes four times a week, a researcher said here. (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 19, 2013 Category: Psychiatry Source Type: news
FDA Approves ADHD Drug for Maintenance Treatment in KidsFDA Approves ADHD Drug for Maintenance Treatment in Kids
The FDA has approved lisdexamfetamine dimesylate capsules for ADHD maintenance treatment in children and adolescents. Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - May 2, 2013 Category: Psychiatry Tags: Psychiatry News Source Type: news
Attention-Deficit Drugs Face New Campus Rules
Fresno State is one of dozens of colleges tightening the rules on the diagnosis of A.D.H.D. and the subsequent prescription of amphetamine-based medications like Vyvanse and Adderall. Some schools are reconsidering how their student health offices handle A.D.H.D., and even if they should at all. (Source: RWJF News Digest - Public Health)
Source: RWJF News Digest - Public Health - April 30, 2013 Category: American Health Source Type: news
Adult demand for ADD drug lifts Shire
Vyvanse, its most recent attention deficit disorder medicine, became a ‘blockbuster’ drug, generating sales up 28 per cent to $1bn last year (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 14, 2013 Category: Pharmaceuticals Source Type: news
Elvanse® (lisdexamfetamine dimesylate) receives UK marketing authorisation for the treatment of ADHD in children and adolescents
Source: Shire plc
Area: News
The MHRA has granted a marketing authorisation to Shire plc for Elvanse® (lisdexamfetamine dimesylate) for the treatment of attention deficit/hyperactivity disorder (ADHD) in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate. Lisdexamfetamine is a once daily long-acting prodrug stimulant, which is due to be launched in the UK at the beginning March (further details on formulations, cost, dosing etc will not be available untill product launch). (Source: NeLM - Mental Health)
Source: NeLM - Mental Health - February 14, 2013 Category: Psychiatry Source Type: news
Elvanse® (Lisdexamfetamine Dimesylate) Receives UK Marketing Authorisation - New Option For The Treatment Of ADHD In Children And Adolescents
Shire plc (LSE: SHP, NASDAQ: SHPG) have announced that its single-daily dose long-acting prodrug stimulant, Elvanse, has been authorised by the MHRA for the treatment of ADHD in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.2 Elvanse is the first stimulant prodrug to be launched in Europe for the treatment of ADHD. It is ingested in an inactive form and subsequently activated within the body, meaning that the active part of Elvanse is gradually released over time... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 13, 2013 Category: Consumer Health News Tags: ADHD Source Type: news
When 'Study Drugs' Kill (Part 2): Reducing The Risks From Brain-Doping
When people choose to use powerful, and potentially dangerous, stimulant medications to enhance cognitive functioning they need to manage the risks. While medications like Adderall and Vyvanse can be life-saving for those who suffer with an attention-deficit disorder, when people who are not afflicted with such a disorder use the same meds to enhance attention and concentration for work or school there are serious risks and dangers that must be managed. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 10, 2013 Category: Pharmaceuticals Authors: Todd Essig Source Type: news
When 'Study Drugs' Kill (Part 1): How Ambition Becomes Adderall Addiction
The story could not be more awful; a downward spiral of amphetamine addiction ends in suicide. But it wasn’t Black Beauties or crystal meth, or any kind of street speed. It was so-called “study drugs” like Vyvanse and Adderall, all prescribed by a series of psychiatrists thinking they were doing good while doing harm. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - February 10, 2013 Category: Pharmaceuticals Authors: Todd Essig Source Type: news
Essential reading: NY Times on the dark side of Adderall and other prescription stimulants
A superb piece in this Sunday’s New York Times tells in gripping and heartbreaking detail how casual prescribing of Adderall and other stimulant drugs can lead to catastrophe. The article is structured like a Greek tragedy, with the reader — like the victim’s family — seeing where the narrative is leading but powerless to do anything to derail it.
The author, Alan Schwarz, lets us in on what to expect from the beginning:
The story of Richard Fee, an athletic, personal college class president and aspiring medical student, highlights widespread failing in the system through which five million Americans take ...
Source: The Poison Review - February 5, 2013 Category: Toxicology Authors: Leon Tags: Medical adder all ADHD alan schwarz attention deficit hyperactivity disorder new york times vyvanse Source Type: news
